The following drug companies made headlines this past week.
1. Hospira recall exacerbates ongoing baking soda shortage: 4 things to know
Hospira recalled 42 lots of sodium bicarbonate solution last week over potential issues with their sterility, worsening an ongoing critical shortage of the crucial drug.
2. Patients seeking financial assistance for $750k Biogen drug must sign away PHI
For patients with spinal muscular dystrophy, affordable treatment comes at a cost.
3. SCOTUS decision reduces drugmakers' product liability
The U.S. Supreme Court sided with Bristol-Myers Squibb on June 19 in a case that could make it more difficult for patients to sue major corporations in state courts over injuries caused by the companies' products.
4. Why this drugmaker invests in clean coal
Mylan banks on more than just prescription medications to make a profit. The drugmaker has achieved hundreds of millions of dollars in tax credits over the last six years by investing in refined coal.
5. Lucid Pharma recalls 69k bottles of antidepressant over quality issues
Lucid Pharmaceuticals recalled more than 69,000 bottles of its extended-release antidepressant drug cenlafaxine hydrochloride over quality concerns.
6. Merck, Premier expand partnership with preventative care, chronic disease initiatives
Merck and Premier will build on an existing partnership to create and test the efficacy of data-driven care solutions for at-risk patient populations.
More articles on supply chain:
Philips acquires noninvasive neurodiagnostics company for $36M
GOP Senators take aim at device tax in healthcare bill
7 latest FDA approvals